These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35861622)

  • 1. A flexible approach for predictive biomarker discovery.
    Boileau P; Qi NT; van der Laan MJ; Dudoit S; Leng N
    Biostatistics; 2023 Oct; 24(4):1085-1105. PubMed ID: 35861622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Biomarkers in Renal Cell Carcinoma.
    Saliby RM; Saad E; Kashima S; Schoenfeld DA; Braun DA
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430734. PubMed ID: 38207251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic biomarkers in renal cell carcinoma.
    Jiang Z
    Expert Rev Mol Diagn; 2007 May; 7(3):293-307. PubMed ID: 17489736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal cancer biomarkers. What is justified?].
    Moch H
    Pathologe; 2012 Nov; 33 Suppl 2():278-81. PubMed ID: 23052348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine for metastatic renal cell carcinoma.
    Sonpavde G; Choueiri TK
    Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
    Osunkoya AO; Yin-Goen Q; Phan JH; Moffitt RA; Stokes TH; Wang MD; Young AN
    Hum Pathol; 2009 Dec; 40(12):1671-8. PubMed ID: 19695674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
    Romero-Laorden N; Doger B; Hernandez M; Hernandez C; Rodriguez-Moreno JF; Garcia-Donas J
    Clin Transl Oncol; 2016 Jan; 18(1):1-8. PubMed ID: 26169213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarkers for renal cell tumours].
    Zeuschner P; Zaccagnino A; Junker K
    Aktuelle Urol; 2021 Sep; 52(5):452-463. PubMed ID: 34157774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.
    Ternès N; Rotolo F; Michiels S
    BMC Med Res Methodol; 2017 May; 17(1):83. PubMed ID: 28532387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
    Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
    BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future.
    Gan CL; Dudani S; Heng DYC
    Cancer J; 2020; 26(5):365-375. PubMed ID: 32947304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient screening of predictive biomarkers for individual treatment selection.
    Sugasawa S; Noma H
    Biometrics; 2021 Mar; 77(1):249-257. PubMed ID: 32294246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Future Biomarkers in the Management of Renal Cell Carcinoma.
    Reese S; Calderon L; Khaleel S; Hakimi AA
    Urol Clin North Am; 2023 Feb; 50(1):151-159. PubMed ID: 36424079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of cross-omics screening for kidney clear cell renal cancer survival.
    Dimitrieva S; Schlapbach R; Rehrauer H
    Biol Direct; 2016 Dec; 11(1):68. PubMed ID: 27993167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma.
    Kubiliūtė R; Žukauskaitė K; Žalimas A; Ulys A; Sabaliauskaitė R; Bakavičius A; Želvys A; Jankevičius F; Jarmalaitė S
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):361-375. PubMed ID: 34689221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal papillary cell carcinoma.
    Yao ZY; Xing CQ; Zhang T; Liu YW; Xing XL
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2235-2244. PubMed ID: 33755961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic utility of amylase α-1A, MOC 31, and
    Abouhashem NS; Abdelbary EH; H Abdalla MM; El-Shazly M
    Indian J Pathol Microbiol; 2020; 63(3):405-411. PubMed ID: 32769329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.